Germany’s Merck is considering the future of its consumer health segment, including a potential full or partial sale of the business as well as new strategic partnerships.
Highlighting the success of the business, Merck said it booked net sales of 860 million euros in 2016.
But while having “maintained a solid position in attractive markets” and “a pattern of profitable growth,” the firm expects “increasing internal constraints to fund the business to reach the required scale,” said Belén Garijo, member of the Executive Board of Merck and chief executive of Healthcare.
“Fully anticipating this, we are preparing strategic options,” he added.
The group also noted that any move would form an “important step” in executing its science and technology focused strategy, and that any proceeds from a potential transaction would be used to deliver on its overall financial targets.
